NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM
Delisted
NGM was delisted on the 4th of April, 2024.
122 hedge funds and large institutions have $200M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 44 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
19% less capital invested
Capital invested by funds: $246M → $200M (-$45.7M)
Holders
122
Holding in Top 10
3
Calls
$124K
Puts
$9K
Top Buyers
| 1 | +$1.46M | |
| 2 | +$1.22M | |
| 3 | +$835K | |
| 4 |
Morgan Stanley
New York
|
+$793K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$707K |
Top Sellers
| 1 | -$4.4M | |
| 2 | -$3.31M | |
| 3 | -$841K | |
| 4 |
Goldman Sachs
New York
|
-$771K |
| 5 |
Man Group
London,
United Kingdom
|
-$690K |